PDGFRB and renal cell carcinoma: As sorafenib has a strong anti-angiogenic effect with suppression of the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), it is markedly effective for RCC (26,42).